ADMINISTRATION ABSTRACT The Knight Cancer Institute is a matrix organization within OHSU. The Cancer Center Support Grant (CCSG) has been effectively managed by the administrative office under the leadership of the OHSU Knight Cancer Institute Director, Brian Druker, M.D. The past several years have brought tremendous positive change to the cancer institute, including the appointment of world-renowned scientists to serve as Knight senior leaders, recruitment of 32 new cancer researchers, reorganization of research programs, development of an expanded vision for early cancer detection, and successful completion of a $1 billion philanthropic fundraising challenge campaign. The Knight administration plays a critical role in providing resources and expertise to support the strategic initiatives and ongoing operations of the Knight Cancer Institute. The Knight administrative team is led by Kristin Bialobok, Associate Director Administration, who oversees all central operations. Working to prevent duplication, and ensure integration and coordination with the larger OHSU structure, the Knight administrative office acts as a liaison to OHSU central service groups, divisions, and departments across campus. Key activities overseen by the Knight center administrative office include 1) fiscal and grants management; 2) shared resource oversight and support; 3) CCSG membership processes and activities; 4) space management; 3) planning and evaluation activities; 4) strategic communications; 5) business development and commercialization support; 6) information technology support and development; 7) general administration, human resources, and events coordination; 8) communication outreach and engagement; 9) pilot project administration, 10) faculty recruitment management; and 11) organizational development. In the current funding cycle, the Knight administrative team made multiple substantial contributions. Examples of these contributions include: 1) development of a scientific research advocate group; 2) creation and launching of a Community Partnership Initiative; 3) facilitation of design and construction preparation activities for a new Knight cancer research building and a new clinical building; 4) development of new Knight membership and publication tracking system (Galen); 5) implementation of a new Competitive Application Portal for management of internal funding opportunities and external limited submission applications; and 6) implementation of iLabs to streamline management of shared resources. The Knight senior leadership team is composed of Director, Brian Druker, MD; Deputy Director, Tomasz Beer, MD; and Associate Directors, Raymond Bergan, MD, Sara A. Courtneidge, PhD, Lisa M. Coussens, PhD, Joe Gray, PhD, Mary Stenzel-Poore, PhD, and Kristin Bialobok, MSN. Together these leaders are responsible for establishing the institute's goals, guiding its strategic initiatives, and ensuring that basic, translational, and population science initiatives are in alignment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA069533-19
Application #
9278517
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-07-01
Budget End
2018-06-30
Support Year
19
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Chen, Emerson Y; Blanke, Charles D; Haller, Daniel G et al. (2018) A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol 41:1193-1198
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028

Showing the most recent 10 out of 277 publications